Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
Avrobio
Avrobio is a clinical-stage gene therapy company developing advanced treatments for cancer and rare diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Abeona Therapeutics
Abeona Therapeutics is developing gene therapies and plasma-based products for life-threatening rare genetic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Nightstar Therapeutics
Nightstar Therapeutics is developing and commercializing one-time retinal gene therapies for rare inherited retinal diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Coave Therapeutics
Coave Therapeutics is a clinical-stage biotechnology company developing gene therapies for rare ocular and CNS diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 08.11.2021. Their latest investor Syncona Partners LLP. Their latest round Corporate Round
Sanofi
Sanofi is a global healthcare company that develops and markets innovative therapeutic solutions.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Syncona Partners LLP
Syncona Partners LLP is a healthcare company that invests in and builds global leaders in life science.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Syncona Partners LLP
Syncona Partners LLP is a healthcare company that invests in and builds global leaders in life science.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Cambridge Innovation Capital
Cambridge Innovation Capital backs life sciences and technology companies in Europe’s leading ecosystem, Cambridge.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Robert Tansley
Robert Tansley has been with CIC since January 2014 and heads up the team that focuses on healthcare and associated technologies. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte®. Robert then joined the Cambridge-based company Arakis and worked as Medical Director until its £106 million sale to Sosei Inc. Since that acquisition, he has been involved in a number of start-up companies, including founding the malaria-focused company Treague and being founding CEO of the University of Copenhagen spin-out Avilex Pharma. In addition he was part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School. Robert qualified in medicine from University College London. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.
current job
T. Rowe Price
T. Rowe Price is an investment management firm that funds technology startups.
Sector
Subsector
Location
count Of Investments
count Of Exists
Acquisitions1
Orbit Biomedical acquired by Gyroscope Therapeutics
acquirer
date
Orbit Biomedical
Orbit Biomedical revolutionizes gene and cell therapy with precise surgical delivery.
Sector
Subsector
Keywords
Location
total rounds
People
Founders3
David Kavanagh
David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC). The NRCTC is a combined clinical, diagnostic and treatment centre for the complement mediated diseases: atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy. All patients in England treated with eculizumab for these diseases are managed through the NRCTC. His University research group has been at the forefront of defining the role of complement in renal disease and is fully integrated with the NRCTC to provide rapid translational benefits to patients. David moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis. He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award. Additionally, he runs a glomerulonephritis and vasculitis clinic at Freeman hospital. He is chairman of the aHUS rare disease working group, an executive committee member of Complement UK
current job
organization founded
David Kavanagh
Peter Lachmann
Sir Peter Lachmann is emeritus Sheila Joan Smith Professor of Immunology at the University of Cambridge, a fellow of Christ’s College, Cambridge and honorary fellow of Trinity College, Cambridge and of Imperial College. He was knighted for service to medical science in 2002. He has won numerous international accolades including a Gold Medal from the European Complement Network in 1997, the Medicine and Europe Senior Prize, Academie des Sciences de la Santé in 2003. His primary research interest now is the downregulation of the complement alternative pathway as a treatment for age related macular degeneration. he has previously worked on many aspects of complement biology; on microbial subversion of the innate immune response; on the immunology of measles, on systemic lupus erythematosus and on insect sting allergies.
current job
organization founded
Peter Lachmann
Andrew Lotery
Andrew is Professor of Ophthalmology at the University of Southampton, Director of the Clinical Neurosciences Research Group and an Honorary Consultant Ophthalmologist at University Hospital Southampton NHS Foundation Trust. Andrew’s scientific research is within the genetic associations of eye disease, with his clinical research focussed on AMD. He has one of the largest patient data-sets and clinical sample banks in the UK. He is the chief investigator on Roche’s Phase 3 trial of lampalizumab for dry AMD and was a co-investigator on the first clinical gene therapy trial for choroideremia. Andrew is an Observer at the Gyroscope Board of Directors.
current job
organization founded
Andrew Lotery
Employee Profiles10
Arman Nadershahi
Senior Director, Associate General Counsel
David Kavanagh
Professor of Nephrology, Newcastle, Academic Founder
Andrew Lotery
Professor of Ophthalmology, University of Southampton, Academic Founder
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range